Aurinia Pharmaceuticals (AUPH) said Tuesday that an experimental medicine for dry-eye syndrome proved to be more effective but slightly less tolerable than Restasis, the best-selling treatment marketed by Allergan.
The Aurinia dry-eye drug is called VOS, and the reported clinical trial results were basically the opposite of what the company expected. Technically, the VOS study failed on tolerability — the primary goal.
Hi Adam….big fan of yours….high school education from Greece….restaurant business…..I try to understand things but it is hard especially in biotech….just a simple question….are you still kinda positive on aurinia….?…it is fine if you do not answer to this question for any reason….I know how busy you are…..god bless.
Comments are closed.